Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) CFO Sells 188 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) CFO Jamie Samath sold 188 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $566.94, for a total transaction of $106,584.72. Following the completion of the transaction, the chief financial officer now owns 7,162 shares of the company’s stock, valued at approximately $4,060,424.28. This represents a 2.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jamie Samath also recently made the following trade(s):

• On Monday, February 10th, Jamie Samath sold 269 shares of Intuitive Surgical stock. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00.
• On Wednesday, January 29th, Jamie Samath sold 94 shares of Intuitive Surgical stock. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34.
• On Tuesday, December 10th, Jamie Samath sold 270 shares of Intuitive Surgical stock. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50.

Intuitive Surgical Trading Down 1.1 %

Shares of NASDAQ:ISRG opened at $566.98 on Tuesday. The stock has a market capitalization of $201.95 billion, a P/E ratio of 88.45, a P/E/G ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The business has a 50-day moving average price of $570.66 and a two-hundred day moving average price of $530.08.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $670.00 target price (up previously from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Bernstein Bank increased their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. Leerink Partners increased their target price on shares of Intuitive Surgical from $490.00 to $548.00 in a research report on Monday, January 27th. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Finally, Evercore ISI upped their target price on shares of Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $613.10.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently modified their holdings of the stock. Atala Financial Inc acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $26,000. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $26,000. BankPlus Trust Department acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Finally, Hurley Capital LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $28,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.